Canadian pharmaceutical company Apotex Health Corp (TSX:APTX) announced on Monday the US launch of Axitinib Tablets, 1 mg and 5 mg, the first generic version of Pfizer's INLYTA, a kinase inhibitor indicated for the treatment of advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.
Renal cell carcinoma is the most common type of kidney cancer in adults and accounts for approximately 90% of kidney cancer diagnoses. Axitinab Tablets provide an additional FDA-approved treatment option for appropriate patients with advanced RCC following failure of one prior systemic therapy.
Axitinib Tablets are supplied as 1 mg tablets in bottles of 180 (NDC 60505-4427-8) and 5 mg tablets in bottles of 60 (NDC 60505-4428-6).
ViiV Healthcare receives positive EU recommendation for expanded paediatric HIV treatments
Rezolute's ersodetug meets primary endpoint in Phase 3 upLIFT study of tumour hyperinsulinism
Sunnyside adds GLP-1 options to its medication program for Alcohol Use Disorder
Traws Pharma reports final Phase 2a COVID-19 data and advances influenza programme
Shanton Pharma's SAP-001 receives EMA and FDA paediatric study waivers in hyperuricaemia
Ascletis announces submission of US IND application for oral obesity combination therapy
bioMérieux secures FDA clearance and IVDR CE marking for VITEK PRO diagnostic platform
Compass Pathways completes FDA application for COMP360 in treatment-resistant depression
bioMérieux secures FDA clearance for updated gastrointestinal diagnostic panels
Photocure maintains 2028 Medicare coverage target for AssureMDx following CMS update